HSG4112

DRUG5 trials

Sponsors

Glaceum

Conditions

Obesity

Phase 1

A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112

CompletedNCT04703764

Start: 2021-02-15End: 2022-02-03Updated: 2022-09-09

A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112

CompletedNCT04733001

Start: 2020-07-12End: 2021-02-10Updated: 2021-09-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112

CompletedNCT04732988

Start: 2018-08-23End: 2021-05-24Updated: 2021-11-01

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

CompletedNCT05310032

Start: 2022-04-21End: 2023-03-31Updated: 2024-03-20

Phase 2

A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients

CompletedNCT05197556

Start: 2022-02-24End: 2023-04-04Updated: 2024-03-19

Related Papers

Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial

Frontiers in Pharmacology2023-08-241 citations